XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table summarizes the changes in the carrying amount of goodwill:

(in millions)						Amount
Balance at December 31, 2020						$	8,108
Goodwill resulting from the acquisition of MYR						226
Measurement period adjustments						(2)
Balance at September 30, 2021						$	8,332

Schedule of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

						September 30, 2021																								December 31, 2020
(in millions)						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir						$	10,720					$	(5,477)					$	—					$	5,243					$	10,720					$	(4,952)					$	—					$	5,768
Intangible asset - axicabtagene ciloleucel(1)						7,110						(1,400)						—						5,710						6,200						(1,105)						—						5,095
Intangible asset - Trodelvy(2)						5,630						(390)						—						5,240						4,600						(63)						—						4,537
Intangible asset - Hepcludex						845						(50)						—						795						—						—						—						—
Other						1,410						(619)						1						792						1,377						(540)						(1)						836
Total finite-lived assets						25,715						(7,936)						1						17,780						22,897						(6,660)						(1)						16,236
Indefinite-lived assets - IPR&D(1)(2)(3)(4)						16,120						—						—						16,120						16,890						—						—						16,890
Total intangible assets						$	41,835					$	(7,936)					$	1					$	33,900					$	39,787					$	(6,660)					$	(1)					$	33,126

_______________________________

(1)     Gross carrying amount as of September 30, 2021 includes $910 million reclassified from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

(2)     Gross carrying amount as of September 30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (“UC”) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D.

(3)     Gross carrying amount as of September 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.

(4)     In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million will be reclassified to finite-lived assets in the fourth quarter of 2021.

Schedule of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

						September 30, 2021																								December 31, 2020
(in millions)						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir						$	10,720					$	(5,477)					$	—					$	5,243					$	10,720					$	(4,952)					$	—					$	5,768
Intangible asset - axicabtagene ciloleucel(1)						7,110						(1,400)						—						5,710						6,200						(1,105)						—						5,095
Intangible asset - Trodelvy(2)						5,630						(390)						—						5,240						4,600						(63)						—						4,537
Intangible asset - Hepcludex						845						(50)						—						795						—						—						—						—
Other						1,410						(619)						1						792						1,377						(540)						(1)						836
Total finite-lived assets						25,715						(7,936)						1						17,780						22,897						(6,660)						(1)						16,236
Indefinite-lived assets - IPR&D(1)(2)(3)(4)						16,120						—						—						16,120						16,890						—						—						16,890
Total intangible assets						$	41,835					$	(7,936)					$	1					$	33,900					$	39,787					$	(6,660)					$	(1)					$	33,126

_______________________________

(1)     Gross carrying amount as of September 30, 2021 includes $910 million reclassified from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

(2)     Gross carrying amount as of September 30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (“UC”) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D.

(3)     Gross carrying amount as of September 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.

(4)     In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million will be reclassified to finite-lived assets in the fourth quarter of 2021.

Schedule of Estimated Future Amortization Expense

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September 30, 2021:

(in millions)						Amount
2021 (remaining three months)						$	441
2022						1,764
2023						1,764
2024						1,764
2025						1,759
Thereafter						10,288
Total						$	17,780

X

- References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

+ Details

Name:	us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b),(d)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration